IL6 and urinary bladder carcinoma: Given the data above revealed sertindole as an inhibitor of STAT3 activation, either inherent in cells or induced by IL-6, we then asked whether sertindole-induced bladder cancer cytotoxicity was compromised if STAT3 remains active in sertindole-treated cells.